Darunavir and Dabigatran etexilate (Pradaxa 110 mg): interaction and safety
This source-based reference is not a personal treatment recommendation. The relevance and management of an interaction depend on the exact products, route, dose and clinical situation.
Interaction mechanism
P-glycoprotein inhibition can increase dabigatran exposure.
Clinical significance and safety
For ritonavir-boosted darunavir (PREZISTA/ritonavir), dabigatran needs assessment of kidney function, indication and its applicable label. Monitoring and suitability should be decided by the prescriber because bleeding risk may increase.
Using this information
This is a source-based reference record, not a recommendation to combine, stop or change medicines. A missing interaction record does not establish safe use. A qualified healthcare professional should consider the exact products, doses, other medicines and individual health circumstances.